Isomorphic Labs, a spinout from DeepMind, is reportedly in early discussions to raise new capital at a valuation between $40 billion and $50 billion. This potential funding round follows a $2.1 billion investment secured in May 2025, which brought the company's total external funding to $2.7 billion.
Founded in 2021 by Demis Hassabis, the London-based company utilizes its proprietary IsoDDE engine for drug discovery. The startup focuses on developing treatments for cancer and immune disorders, maintaining partnerships with major pharmaceutical firms including Eli Lilly, Novartis, and Johnson & Johnson.
The company operates offices in London, Cambridge, Massachusetts, and Lausanne, Switzerland. As of May 2025, the organization employed more than 350 staff members. The leadership team includes Demis Hassabis and president Max Jaderberg.
The firm's previous funding rounds included a $600 million investment in March 2025 and the $2.1 billion Series B round in May 2025. Investors in these rounds included Thrive Capital, GV, Alphabet, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
Isomorphic Labs aims to initiate its first clinical trials by the end of 2026. The company's progress is part of a broader trend in the AI drug discovery sector, which also includes competitors such as Chai Discovery, Xaira Therapeutics, and Basecamp Research.
